Guidelines for elective percutaneous coronary intervention in patients with stable coronary artery disease (JCS 2011) published in 2012: Digest version

Circulation Journal

Volumn 77, Issue 6, 2013, Pages 1590-1607

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFECTIVE AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NITRATE; NONSTEROID ANTIINFLAMMATORY AGENT; TICLOPIDINE;

ANGIOGRAPHY; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; CREATINE KINASE BLOOD LEVEL; FALSE ANEURYSM; FOLLOW UP; HEALTH CARE COST; HEALTH INSURANCE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEMATOMA; HUMAN; ISCHEMIA; KIDNEY DISEASE; LIFESTYLE; LOADING DRUG DOSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; STENT THROMBOSIS; TREATMENT OUTCOME;

CORONARY ARTERY DISEASE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION;

EID: 84878244208     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-66-0065     Document Type: Article

References (90)

1. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (1998-1999 Joint Working Groups Report). Guidelines on Indications of Elective Intervention (including CABG) in the Treatment of Coronary Artery Disease. Jpn Circ J 2000; 64(Suppl 4): 1009-1022 (in Japanese).
2. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2004-2005 Joint Working Groups Report). Guidelines for the Clinical Application of Bypass Grafts and the Surgical Techniques (JCS 2006). Circ J 2006; 70(Suppl 4): 1477-1553 (in Japanese).
3. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al; Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Guidelines on myocardial re-vascularization. Eur Heart J 2010; 31: 2501-2555.
4. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronay artery disease: A meta-analysis. Circulation 2005; 111: 2906-2912.
5. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356: 1503-1516.
6. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515.
7. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, et al; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. The Bypass Angioplasty Revascular-ization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myo-cardial infarction. Circulation 2009; 120: 2529-2540.
8. Weintraub WS, Spertus JA, Kolm P, Maron DJ, Zhang Z, Jurkovitz C, et al; COURAGE Trial Research Group. Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med 2008; 359: 677-687.
9. Nishigaki K, Yamazaki T, Kitabatake A, Yamaguchi T, Kanmatsuse K, Kodama I, et al; Japanese Stable Angina Pectoris Study Investigators. Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease: A randomized, comparative, multicenter study. JACC Cardiovasc Interv 2008; 1: 469-479.
10. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and effcacy of drug-eluting and bare metal stents: Comprehensive meta-analysis of randomized trials and observational studies. Circulation 2009; 119: 3198-3206.
11. Trikalinos TA, Alsheikh-Ali AA, Tatsioni A, Nallamothu BK, Kent DM. Percutaneous coronary interventions for non-acute coronary artery disease: A quantitative 20-year synopsis and a network meta-analysis. Lancet 2009; 373: 911-918.
12. Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomized trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344: 563-570.
13. Cameron A, Davis KB, Green G, Schaff HV. Coronary bypass surgery with internal-thoracic-artery grafts--effects on survival over a 15-year period. N Engl J Med 1996; 334: 216-219.
14. Taggart DP, D'Amico R, Altman DG. Effect of arterial revasculari-sation on survival: A systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 2001; 358: 870-875.
15. Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, et al. Five-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2007; 115: 1082-1089.
16. Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, et al. Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): A randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation 2010; 122: 949-957.
17. Brooks MM, Chung SC, Helmy T, Hillegass WB, Escobedo J, Melsop KA, et al; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group. Health status after treatment for coronary artery disease and type 2 diabetes mellitus in the Bypass Angio-plasty Revascularization Investigation 2 Diabetes trial. Circulation 2010; 122: 1690-1699.
18. Gersh BJ, Frye RL. Methods of coronary revascularization--things may not be as they seem. N Engl J Med 2005; 352: 2235-2237.
19. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961-972.
20. Kappetein AP, Feldman TE, Mack MJ, Morice MC, Holmes DR, Ståhle E, et al. Comparison of coronary bypass surgery with drug- eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial. Eur Heart J 2011; 32: 2125-2134.
21. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: A collaborative analysis of individual patient data from ten randomised trials. Lancet 2009; 373: 1190-1197.
22. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. Circulation 2008; 118(14 Suppl): S199-S209.
23. Hannan EL, Wu C, Walford G, Culliford AT, Gold JP, Smith CR, et al. Drug-eluting stents vs. coronary-artery bypass grafting in multi-vessel coronary disease. N Engl J Med 2008; 358: 331-341.
24. Marui A, Kimura T, Tanaka S, Furukawa Y, Kita T, Sakata R; CREDO-Kyoto Investigators. Siginifcance of off-pump coronary artery bypass grafting compared with percutaneous coronary intervention: A propensity score analysis. Eur J Cardiothorac Surg 2012; 41: 94-101.
25. Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011; 364: 1718-1727.
26. Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF/ SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. Circulation 2009; 119: 1330-1352.
27. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al; American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
28. Toyofuku M, Kimura T, Morimoto T, Hayashi Y, Ueda H, Kawai K, et al; j-Cypher Registry Investigators. Three-year outcomes after si-rolimus-eluting stent implantation for unprotected left main coronary artery disease: Insights from the j-Cypher registry. Circulation 2009; 120: 1866-1874.
29. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2010 Joint Working Groups Report). Guidelines for the Clinical Application of Bypass Grafts and the Surgical Techniques (JCS 2011). http://www.j-circ.or.jp/guideline/pdf/JCS2011_ochi_h.pdf (in Japanese).
30. Expository text of National Health Insurance price list for medical services. April 2012 version. Chapter 2. Special medical service fee. Section 10. Surgeries. Item 8. Cardiac and vascular surgeries. Tokyo: Shakai Hoken Kenkyujo Co., Ltd., 2010; 640-643 (in Japanese).
31. World Health Organization Statistics Core Health Indicators. Age-standardized mortality rate for cardiovascular disease. http://www.who.int/whosis/database/core/core_select.cfm (available in February 2012).
32. Fujishima M. Ideal way of multicentrer clinical trial: Science and ethics: From the experience of epidemiology at Hisayama town. J Jpn Soc Intern Med 1997; 86: 1675-1679 (in Japanese).
33. Nishigaki K, Yamazaki T, Fujiwara H; Japanese Coronary Intervention Study (JCIS) Group. Assessment of coronary intervention in Japan from the Japanese Coronary Intervention Study (JCIS) Group. Circ J 2004; 68: 181-185.
34. JCRAC (Joint Center for Researchers, Associates and Clinicians) Data Center. JCS National Survey on Management of Cardiovascular Diseases: Annual Report 2009. http://www.j-circ.or.jp/jittai_chosa/jittai_chosa2009web.pdf (in Japanese).
35. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. Circulation 2008; 118(14 Suppl): S199-S209.
36. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al; American College of Cardiology/American Heart Asso- ciation task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty); Society for Cardiac Angiography and Interventions. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103: 3019-3041.
37. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667-678.
38. Popma JJ, Kuntz RE, Baim DS. Percutaneous coronary and valvular intervention. In: Braunwald E, Zipes DP, Libby P, Bonow RO, editors. Heart Disease. A textbook of cardiovascular medicine. Philadelphia: W.B.Saunders, 2005: 1377-1380.
39. Kuntz RE, Safan RD, Levine MJ, Reis GJ, Diver DJ, Baim DS. Novel approach to the analysis of restenosis after the use of three new coronary devices. J Am Coll Cardiol 1992; 19: 1493-1499.
40. Criteria specifed by the MHLW for institutions providing PTCA (PCI; percutaneous coronary angioplasty, percutaneous coronary thrombectomy, and percutaneous coronary stenting). Notifcation No. 86 of The Medical Economics Division of the Health Insurance Bureau dated May 22, 2000 (in Japanese).
41. Criteria for institutions providing percutaneous coronary angioplasty (No. 63) using percutaneous transluminal coronary rotational ablation. Notifcation No. 0305-3 of The Medical Economics Division of the Health Insurance Bureau dated March 5, 2010 (in Japanese).
42. Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, et al. Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction: The SWISSI II randomized controlled trial. JAMA 2007; 297: 1985-1991.
43. Folland ED, Hartigan PM, Parisi AF. Percutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: Outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial: Veterans Affairs ACME InvestigatorS. J Am Coll Cardiol 1997; 29: 1505-1511.
44. Coronary angioplasty versus medical therapy for angina: The second Randomised Intervention Treatment of Angina (RITA-2) trial: RITA-2 trial participants. Lancet 1997; 350: 461-468.
45. Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, et al; Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: Coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003; 42: 1161-1170.
46. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revasculariza-tion Treatment Investigators. N Engl J Med 1999; 341: 70-76.
47. Bogart DB, Bogart MA, Miller JT, Farrar MW, Barr WK, Montgomery MA. Femoral artery catheterization complications: A study of 503 consecutive patients. Cathet Cardiovasc Diagn 1995; 34: 8-13.
48. Agrawal SK, Pinheiro L, Roubin GS, Hearn JA, Cannon AD, Macander PJ, et al. Nonsurgical closure of femoral pseudoaneurysms complicating cardiac catheterization and percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1992; 20: 610-615.
49. Feld R, Patton GM, Carabasi RA, Alexander A, Merton D, Needleman L. Treatment of iatrogenic femoral artery injuries with ultrasound-guided compression. J Vasc Surg 1992; 16: 832-840.
50. Schaub F, Theiss W, Heinz M, Zagel M, Schömig A. New aspects in ultrasound-guided compression repair of postcatheterization femoral artery injuries. Circulation 1994; 90: 1861-1865.
51. Mann T, Cowper PA, Peterson ED, Cubeddu G, Bowen J, Giron L, et al. Transradial coronary stenting: Comparison with femoral access closed with an arterial suture device. Catheter Cardiovasc Interv 2000; 49: 150-156.
52. Koreny M, Riedmüller E, Nikfardjam M, Siostrzonek P, Müllner M. Arterial puncture closing devices compared with standard manual compression after cardiac catheterization: Systematic review and meta-analysis. JAMA 2004; 291: 350-357.
53. Simpfendorfer C, Belardi J, Bellamy G, Galan K, Franco I, Hollman J. Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplas-ty. Am J Cardiol 1987; 59: 267-269.
54. de Feyter PJ, de Jaegrere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643-651.
55. Klein LW, Kramer BL, Howard E, Lesch M. Incidence and clinical signifcance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary an-gioplasty. J Am Coll Cardiol 1991; 17: 621-626.
56. Kong TQ, Davidson CJ, Meyers SN, Tauke JT, Parker MA, Bonow RO. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997; 277: 461-466.
57. Hong MK, Mehran R, Dangas G, Mintz GS, Lansky AJ, Pichard AD, et al. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 1999; 100: 2400-2405.
58. Guidelines for the Diagnosis and Treatment of Cardiovascular Diseases (2010 Joint Working Groups Report). Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). http://www.j-circ.or.jp/guideline/pdf/JCS2011_ogawah_h.pdf (in Japanese).
59. Japan Atherosclerosis Society. Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases, 2007 Edition (in Japanese).
60. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for exercise testing: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106: 1883-1892.
61. Hecht HS, DeBord L, Shaw R, Dunlap R, Ryan C, Stertzer SH, et al. Usefulness of supine bicycle stress echocardiography for detection of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1993; 71: 293-296.
62. Fioretti PM, Pozzoli MM, Ilmer B, Salustri A, Cornel JH, Reijs AE, et al. Exercise echocardiography versus thallium-201 SPECT for assessing patients before and after PTCA. Eur Heart J 1992; 13: 213-219.
63. Tan WA, Tamai H, Park SJ, Plokker HW, Nobuyoshi M, Suzuki T, et al; ULTIMA Investigators. Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation 2001; 104: 1609-1614.
64. Silvestri M, Barragan P, Sainsous J, Bayet G, Simeoni JB, Roquebert PO, et al. Unprotected left main coronary artery stenting: Immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol 2000; 35: 1543-1550.
65. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease: Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
66. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease: Benestent Study Group. N Engl J Med 1994; 331: 489-495.
67. Kimura T, Kaburagi S, Tamura T, Yokoi H, Nakagawa Y, Yokoi H, et al. Remodeling of human coronary arteries undergoing coronary angioplasty or atherectomy. Circulation 1997; 96: 475-483.
68. Dussaillant GR, Mintz GS, Pichard AD, Kent KM, Satler LF, Popma JJ, et al. Small stent size and intimal hyperplasia contribute to reste-nosis: A volumetric intravascular ultrasound analysis. J Am Coll Car-diol 1995; 26: 720-724.
69. Serruys PW, Kay IP, Disco C, Deshpande NV, de Feyter PJ. Peripro-cedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: Results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials: Multi-center Ultrasound Stent In Coronaries. J Am Coll Cardiol 1999; 34: 1067-1074.
70. Ellis SG, Savage M, Fischman D, Baim DS, Leon M, Goldberg S, et al. Restenosis after placement of Palmaz-Schatz stents in native coronary arteries: Initial results of a multicenter experience. Circulation 1992; 86: 1836-1844.
71. Erbel R, Haude M, Höpp HW, Franzen D, Rupprecht HJ, Heublein B, et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty: Restenosis Stent Study Group. N Engl J Med 1998; 339: 1672-1678.
72. Kereiakes DJ, Midei M, Hermiller J, O'Shaughnessy C, Schlofmitz R, Yakubov S, et al. Procedural and late outcomes following MULTI-LINK DUET coronary stent deployment. Am J Cardiol 1999; 84: 1385-1390.
73. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996; 334: 561-566.
74. Aoki J, Ikari Y, Sugimoto T, Fukuda S, Hara K. Clinical outcome of percutaneous transluminal coronary rotational atherectomy in patients with end-stage renal disease. Circ J 2003; 67: 617-621.
75. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Interven-tion--summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113: 156-175.
76. De la Torre-Hernández JM, Alfonso F, Hernández F, Elizaga J, Sanmartin M, Pinar E, et al; ESTROFA Study Group. Drug-eluting stent thrombosis: Results from the multicenter Spanish registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmaco-activos). J Am Coll Cardiol 2008; 51: 986-990.
77. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, et al; j-Cypher Registry Investigators. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: Five-year outcome of the j-Cypher Registry. Circulation 2012; 125: 584-591.
78. Schömig A, Dibra A, Windecker S, Mehilli J, De Suárez Lezo J, Kaiser C, et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. J Am Coll Cardiol 2007; 50: 1373-1380.
79. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, et al. Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis. Lancet 2007; 370: 937-948.
80. Kastrati A, Dibra A, Eberle S, Mehilli J, De Suárez Lezo J, Goy JJ, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: Meta-analysis of randomized trials. JAMA 2005; 294: 819-825.
81. De la Torre Hernández JM, Alfonso F, Gimeno F, Diarte JA, Lopez-Palop R, Pérez de Prado A, et al; ESTROFA-2 Study Group. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc Interv 2010; 3: 911-919.
82. Fujii K, Carlier SG, Mintz GS, Yang YM, Moussa I, Weisz G, et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: An intravascular ultrasound study. J Am Coll Cardiol 2005; 45: 995-998.
83. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293: 2126-2130.
84. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere S, et al; EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: The EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 2007; 50: 501-508.
85. Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, et al. Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: The importance of thrombus burden. J Am Coll Cardiol 2007; 50: 573-583.
86. Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, et al; RESTART Investigators. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 2010; 122: 52-61.
87. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al; TAXUS V Investigators. Comparison of a polymer-based pa-clitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223.
88. Tanihata S, Nishigaki K, Kawasaki M, Takemura G, Minatoguchi S, Fujiwara H. Outcomes of patients with stable low-risk coronary artery disease receiving medical- and PCI-preceding therapies in Japan: J-SAP study 1-1. Circ J 2006; 70: 365-369.
89. Sculpher M, Smith D, Clayton T, Henderson R, Buxton M, Pocock S, et al; Randomized Intervention Treatment of Angina (RITA-2) trial. Coronary angioplasty versus medical therapy for angina: Health service costs based on the second Randomized Intervention Treatment of Angina (RITA-2) trial. Eur Heart J 2002; 23: 1291-1300.
90. Ikeda S, Kobayashi M. Economic evaluation of drug-eluting stents in Japan. Keio J Med 2006; 55: 15-22.